FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382048199> ?p ?o ?g. }

• W4382048199 abstract "Pulmonary embolism (PE) has an incidence ranging from four to 12 per 10,000 annually and is a leading cause of cardiovascular mortality in the United States, contributing to nearly 300,000 deaths per year.1-4 Conventional treatment includes heparins, fondaparinux, or vitamin K antagonists (VKAs), but recent data suggest treatment with oral direct thrombin inhibitors (DTIs) or oral factor Xa inhibitors, collectively known as direct oral anticoagulants (DOACs), is effective and safe.5-9 DOACs can be administered orally and have a more predictable effect without the need for monitoring. Here we summarize a recent update to a prior Cochrane review,10 adding 1484 new participants to meta-analyzed data on the subject.11 The Cochrane review included 10 randomized trials comprising 13,073 participants with confirmed PE allocated to treatment with a DOAC or conventional anticoagulation.11 The authors excluded trials not administering oral DOACs, trials not using conventional treatment with heparin and/or VKAs as the comparison, and trials with treatment less than 3 months. Confirmation of PE included computed tomography pulmonary angiography, ventilation/perfusion scan, or pulmonary angiography. DTIs included dabigatran and ximelagatran; factor Xa inhibitors included rivaroxaban, apixaban, betrixaban, and edoxaban; and control agents included low-molecular-weight heparin (LMWH), unfractionated heparin (UFH), or VKAs. Two trials evaluated dabigatran (2553 patients) and eight trials evaluated factor Xa inhibitors (three with apixaban [3307 patients], three with rivaroxaban [2548 patients], and two with edoxaban [2172 patients]). The primary outcome of the review included recurrent venous thromboembolism (VTE), defined variably as clinically overt new deep vein thrombosis (DVT), PE, or either, confirmed by standard imaging during the period after PE diagnosis. Secondary outcomes included all-cause mortality, major bleeding (fatal bleeding, symptomatic bleeding in a critical area, bleeding causing a fall of hemoglobin ≥ 2 g/dL or requiring transfusion of ≥2 units, or any combination of these), and health-related quality of life. Compared to conventional anticoagulation, DTIs led to a similar rate of recurrent PE (two trials, 1602 participants; moderate-certainty evidence), recurrent VTE (two trials, 1602 participants; moderate-certainty evidence), recurrent DVT (two trials, 1602 participants; moderate-certainty evidence), and major bleeding (two trials, 1527 participants; moderate-certainty evidence). Factor Xa inhibitors were also similar to conventional anticoagulation for recurrent PE (three trials, 8186 participants; moderate-certainty evidence), recurrent VTE (eight trials, 11,416 participants; moderate-certainty evidence), recurrent DVT (two trials, 8151 participants; moderate certainty evidence), all-cause mortality (one trial, 4817 participants; moderate-certainty evidence), and major bleeding (eight trials, 11,447 participants; low-certainty evidence). Authors did not evaluate quality of life. There are several important limitations to this systematic review. First, overall outcome event rates were low resulting in wide confidence intervals. While the included trials were mostly of good methodological quality, the certainty of evidence was considered moderate or low. The authors downgraded certainty for both imprecision and heterogeneity in the data. Second, the duration of treatment varied among the studies, ranging from 3 months to 1 year. Third, health-related quality of life was not reported. Fourth, while overall risk of bias was low in eight trials, two trials were at high risk of reporting bias, and six were open label. Current guidelines incorporate treatment of VTE with DOACs due to efficacy, ease of use, and no need for monitoring. The American College of Chest Physicians guidelines recommend DOACs over VKAs for treatment of VTE, and these guidelines also recommend oral factor Xa inhibitors over LMWH for VTE associated with cancer.12, 13 The 2019 European Society of Cardiology also recommends DOACs over VKAs in those requiring treatment for VTE,2 while the NICE 2020 guidelines recommend apixaban or rivaroxaban as the initial anticoagulant of choice.4 Based on these data, there seems to be little or no outcome difference between DOACs and conventional anticoagulation for PE; however, DOACs provide several practical advantages including ease of use, fixed dosing, ability to initiate in the ED without the need for LMWH injections or UFH infusions, and no need for routine laboratory monitoring. Thus, we have provided a color recommendation of green (benefits > harms) for the use of DOACs in treatment of PE. It is difficult to directly compare prices due to variations in dosages, treatment regimens, and local cost data for DOACs versus warfarin14-16; however, in general, DOACs are significantly more expensive than conventional anticoagulation. For example, a 1-month supply of dabigatran costs more than $400, and a 1-month supply of rivaroxaban costs more than $500, though this depends on each individual patient's insurance.17, 18 In contrast, a 1-month supply of 5-mg tablets of warfarin (a traditional VKA) is about $11, though warfarin does require laboratory monitoring, which increases the price of use.19 Also of note, DOAC reversal may be more expensive (idarucizumab for dabigatran and prothrombin complex concentrate [PCC] or andexanet alpha for factor Xa inhibitors) compared to warfarin (vitamin K with fresh-frozen plasma or PCC).20 More studies are necessary to compare DOACs to each other, as well as to evaluate adherence, mortality, safety, quality of life, cost-effectiveness, and tolerability. The authors declare no conflicts of interest." @default.
• W4382048199 created "2023-06-27" @default.
• W4382048199 creator A5018567151 @default.
• W4382048199 creator A5036463797 @default.
• W4382048199 date "2023-07-05" @default.
• W4382048199 modified "2023-09-23" @default.
• W4382048199 title "Direct oral anticoagulants versus conventional anticoagulants for pulmonary embolism" @default.
• W4382048199 cites W1955113749 @default.
• W4382048199 cites W1973598884 @default.
• W4382048199 cites W2105878388 @default.
• W4382048199 cites W2130199362 @default.
• W4382048199 cites W2166402206 @default.
• W4382048199 cites W2225937646 @default.
• W4382048199 cites W2344977044 @default.
• W4382048199 cites W2769275060 @default.
• W4382048199 cites W2804629086 @default.
• W4382048199 cites W2945776346 @default.
• W4382048199 cites W2971121646 @default.
• W4382048199 cites W3189638887 @default.
• W4382048199 cites W4223593767 @default.
• W4382048199 cites W4307429581 @default.
• W4382048199 cites W4317433393 @default.
• W4382048199 doi "https://doi.org/10.1111/acem.14771" @default.
• W4382048199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37363961" @default.
• W4382048199 hasPublicationYear "2023" @default.
• W4382048199 type Work @default.
• W4382048199 citedByCount "0" @default.
• W4382048199 crossrefType "journal-article" @default.
• W4382048199 hasAuthorship W4382048199A5018567151 @default.
• W4382048199 hasAuthorship W4382048199A5036463797 @default.
• W4382048199 hasBestOaLocation W43820481991 @default.
• W4382048199 hasConcept C126322002 @default.
• W4382048199 hasConcept C2776265017 @default.
• W4382048199 hasConcept C2776301958 @default.
• W4382048199 hasConcept C2776710957 @default.
• W4382048199 hasConcept C2776877702 @default.
• W4382048199 hasConcept C2776884760 @default.
• W4382048199 hasConcept C2777292125 @default.
• W4382048199 hasConcept C2777557582 @default.
• W4382048199 hasConcept C2778661090 @default.
• W4382048199 hasConcept C2778810321 @default.
• W4382048199 hasConcept C2779161974 @default.
• W4382048199 hasConcept C2779630707 @default.
• W4382048199 hasConcept C2780149156 @default.
• W4382048199 hasConcept C2780290652 @default.
• W4382048199 hasConcept C2780638905 @default.
• W4382048199 hasConcept C2780868729 @default.
• W4382048199 hasConcept C2991741193 @default.
• W4382048199 hasConcept C57002609 @default.
• W4382048199 hasConcept C71924100 @default.
• W4382048199 hasConcept C89560881 @default.
• W4382048199 hasConceptScore W4382048199C126322002 @default.
• W4382048199 hasConceptScore W4382048199C2776265017 @default.
• W4382048199 hasConceptScore W4382048199C2776301958 @default.
• W4382048199 hasConceptScore W4382048199C2776710957 @default.
• W4382048199 hasConceptScore W4382048199C2776877702 @default.
• W4382048199 hasConceptScore W4382048199C2776884760 @default.
• W4382048199 hasConceptScore W4382048199C2777292125 @default.
• W4382048199 hasConceptScore W4382048199C2777557582 @default.
• W4382048199 hasConceptScore W4382048199C2778661090 @default.
• W4382048199 hasConceptScore W4382048199C2778810321 @default.
• W4382048199 hasConceptScore W4382048199C2779161974 @default.
• W4382048199 hasConceptScore W4382048199C2779630707 @default.
• W4382048199 hasConceptScore W4382048199C2780149156 @default.
• W4382048199 hasConceptScore W4382048199C2780290652 @default.
• W4382048199 hasConceptScore W4382048199C2780638905 @default.
• W4382048199 hasConceptScore W4382048199C2780868729 @default.
• W4382048199 hasConceptScore W4382048199C2991741193 @default.
• W4382048199 hasConceptScore W4382048199C57002609 @default.
• W4382048199 hasConceptScore W4382048199C71924100 @default.
• W4382048199 hasConceptScore W4382048199C89560881 @default.
• W4382048199 hasLocation W43820481991 @default.
• W4382048199 hasLocation W43820481992 @default.
• W4382048199 hasOpenAccess W4382048199 @default.
• W4382048199 hasPrimaryLocation W43820481991 @default.
• W4382048199 hasRelatedWork W1980540237 @default.
• W4382048199 hasRelatedWork W2055018899 @default.
• W4382048199 hasRelatedWork W2078761402 @default.
• W4382048199 hasRelatedWork W2137088071 @default.
• W4382048199 hasRelatedWork W2198902325 @default.
• W4382048199 hasRelatedWork W3168513972 @default.
• W4382048199 hasRelatedWork W4210922264 @default.
• W4382048199 hasRelatedWork W4246422288 @default.
• W4382048199 hasRelatedWork W4382048199 @default.
• W4382048199 hasRelatedWork W78490940 @default.
• W4382048199 isParatext "false" @default.
• W4382048199 isRetracted "false" @default.
• W4382048199 workType "article" @default.